Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20269 Citations
PNC-27 kills cancer cells by forming 34 nm membrane pores after binding surface HDM-2. Active against breast, pancreatic, leukemia, and ovarian lines in preclinical models. Zero human trials exist. FDA issued a 2017 contamination warning. Research-only compound with a safety grade of D.
100mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 4.0 units on a U-100 syringe for a 100mcg dose. This vial will last 50 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 250mcg | Daily |
| Aggressive | 500mcg | Daily |
All dosing is theoretical. Zero human PK data exists for PNC-27. The numbers below come from preclinical IC50 extrapolation and a single murine MTD study. Reconstitution math for a 5 mg vial with 2 mL bacteriostatic water: concentration is 2,500 mcg/mL, so 100 mcg equals 4 units on a U-100 insulin syringe, 250 mcg equals 10 units, and 500 mcg equals 20 units. For a 10 mg vial with 2 mL BAC water: concentration is 5,000 mcg/mL; 100 mcg equals 2 units, 250 mcg equals 5 units, 500 mcg equals 10 units. Swirl the vial gently after adding water. Don't shake it. Peptides are fragile. The thing most people miss: standard apoptosis assays (Annexin V, caspase panels) will give false negatives because PNC-27 kills by necrosis. Use LDH release or propidium iodide exclusion if you're testing cytotoxicity in a research setting. Short half-life means daily dosing is necessary. Reconstituted solution goes in the fridge and should be discarded after 7 days. Lyophilized powder stores at -20 degrees C. Source your vials carefully. The FDA found bacterial contamination in a commercial PNC-27 product in 2017. Require third-party sterility testing from an accredited lab, not just a vendor purity certificate.
Dosing based on Very limited human data: dose based on preclinical research — 16 published references.View all sources →
Cross-check your PNC-27 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
PNC-27 kills cancer cells by forming 34 nm membrane pores after binding surface HDM-2. Active against breast, pancreatic, leukemia, and ovarian lines in preclinical models. Zero human trials exist. FDA issued a 2017 contamination warning. Research-only compound with a safety grade of D.